The Scientist

» IPO

Most Recent

image: Another CRISPR Biotech Goes Public

Another CRISPR Biotech Goes Public

By | September 12, 2016

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Biotech IPOs Surge

Biotech IPOs Surge

By | August 23, 2013

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

0 Comments

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech